Just about a year ago, Blueprint Medicines raised $169 million in Massachusetts' largest biotech IPO. Today, it's got three drugs in clinical trials - and, with a well-padded bank account, has time for a little whimsy.
Calculating the return on investment of expensive drugs and surgeries can mean good news for patients. A recent conversation among decision makers at big insurance companies also showed that payers aren’t the heartless bureaucrats they are often made out to be. Leaders from UnitedHealth Group, Blue Cross Blue Shield Minnesota and Aetna explained how they […]
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Shares of BioSante Pharmaceuticals rose 10 percent after the company reported positive results from a clinical study of a leukemia vaccine. The Phase 2 trial showed that BioSante’s GVAX vaccine “may be able to reduce or eliminate” the last remaining cancer cells in patients who are suffering from chronic myeloid leukemia and taking the drug […]